In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

Illumina has said it will divest cancer detection company Grail, marking the end of a long-running antitrust dispute that has claimed the jobs of its former CEO and chair. The decision was ...

Grail (GRAL) stock shot up 33% Thursday, the day after the company announced a partnership with Quest (DGX) to expand ...

CHICAGO: US cancer diagnostic test maker Grail, which was due to list its shares on the Nasdaq yesterday after being spun out of Illumina, is betting that commercial partnerships with health ...

San Diego gene-sequencing pioneer Illumina on Tuesday won its court fight against the European Union’s investigation of its $7.1 billion purchase of cancer diagnostic test maker Grail ...